U095 Practical Approach to the Diagnosis and Management of Cutaneous Graft Versus Host Disease
DESCRIPTION
Patients who receive allogeneic hematopoietic stem cell transplantation are at significant risk of developing cutaneous graft versus host disease (GVHD). In this session, we will provide practical tips to prepare dermatologists in all practice environments to more confidently approach the evaluation and management of acute and chronic skin GVHD, including expanding the differential diagnosis to consider and exclude other common eruptions such as drug eruptions, toxic erythema of chemotherapy, and nutritional dermatoses in both outpatient and inpatient populations during the post-transplant period. We will also review evidence-based skin-directed management options for GVHD.
LEARNING OBJECTIVES
Diagnose acute and chronic graft versus host disease (GVHD) of the skin, hair, and nails.
Review a comprehensive differential diagnosis for patients who present with skin eruptions after allogeneic hematopoietic stem cell transplant.
Formulate an evidence-based skin-directed treatment plan.
DIRECTOR
Silvina Pugliese, MD, FAAD
SPEAKER
Alina Markova, MD, FAAD
DISCLOSURES
Alina Markova, MD, FAAD
Amryt Pharma – Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Kintara Therapeutics, Inc. – Investigator(Grants/Research Funding); National Institutes of Health – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Novocure – Investigator(Grants/Research Funding); Sanofi Genzyme – Advisory Board(Honoraria); Treeline – Consultant (1099 relationship)(Honoraria); UpToDate – Other(Patent royalties or other compensation for Intellectual Property Rights);
Silvina Pugliese, MD, FAAD
No financial relationships exist with ineligible companies.